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Translational Relevance:  Patients diagnosed with stage I non-seminomatous germ 
cell tumors face a choice between surveillance with treatment at relapse or up-front 
adjuvant therapy. Whilst adjuvant therapy is effective, it may be unneccessary and 
long-term effects of chemotherapy are increasingly recognized. Histological evidence 
of vascular invasion is currently used to target patients for adjuvant therapy, but 
improved markers for risk of relapse are required.  Embryologically, primordial germ 
cells use CXCR12/CXCR4 and KITLG/KIT signaling to migrate to the developing 
gonads. Previously we showed that CXCL12 stimulates migration of germ cell tumor 
cells in a CXCR4-dependent manner and that tumor cell expression of CXCL12 was 
associated with reduced risk of metastatic relapse. Here we validate this finding in a 
large series of samples from patients that underwent surveillance within prospective 
clinical trials and propose CXCL12 expression and percentage of embryonal 
carcinoma as clinically useful biomarkers to assist in stratifying patients for adjuvant 
therapy. 
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Abstract 
 
Purpose: Up to 50% of patients diagnosed with stage I non-seminomatous germ 
cell tumors (NSGCT) harbor occult metastases.  Patients are managed by 
surveillance with chemotherapy at relapse or adjuvant treatment up-front.  Late 
toxicities from chemotherapy are increasingly recognised. Based on a potential 
biological role in germ cells/tumors and pilot data, our aim was to evaluate tumor 
expression of the chemokine CXCL12 alongside previously proposed markers as 
clinically useful biomarkers of relapse. 
 
Experimental design: Immunohistochemistry for tumor expression of CXCL12 
was assessed as a biomarker of relapse alongside vascular invasion, histology 
(percentage embryonal carcinoma) and MIB1 staining for proliferationin formalin 
fixed paraffin-embedded orchidectomy samples from patients enrolled in the 
Medical Research Council’s TE08/22 prospective trials of surveillance in stage I 
NSGCT.  
 
Results: TE08/TE22 trial patients had a 76.4% 2-year relapse free rate (RFR) and 
both CXCL12 expression and percentage embryonal carcinoma provided 
prognostic value independently of vascular invasion (stratified log rank test 
p=0.006 for both).There was no additional prognostic value for MIB1 staining. A 
model using CXCL12, percentage embryonal carcinoma and VI defines 3 
prognostic groups that were independantly validated. 
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Conclusions: CXCL12 and percentage embryonal carcinoma both stratify 
patients’ relapse risk over and above vascular invasion alone.  This is anticipated 
to improve the stratification of patients and identify high-risk cases to be considered 
for adjuvant therapy. 
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Introduction  
Although overall rare cancers, Testicular Germ Cell Tumors (TGCT) are the most 
common solid malignancy to affect young adult Caucasian males.  They are divided 
into seminomas that resemble primordial germ cells or non-seminomas (NSGCT) 
that exhibit embryonal or extra-embryonal patterns of differentiation (1). 60% of 
NSGCT present with stage I disease (confined to the testes) and this proportion is 
increasing (2). 15-50% of such patients may harbor micro-metastatic disease and 
will relapse without further treatment (3, 4). 
 
Assuming protocols are closely adhered to (5), immediate adjuvant treatment (1-2 
cycles of Bleomycin, Etoposide and Cisplatin – BEP (6)) or surveillance with 
chemotherapy as salvage both have excellent rates of cure. Chemotherapy may 
have significant long-term effects including cardiovascular disease (7, 8), second 
malignancies (9, 10), Reynauds syndrome, neuropathies, fertility and emotional 
disorders. For this reason the routine use of adjuvant chemotherapy has been 
criticised in some quarters.  Adjuvant retroperitoneal lymph node dissection is an 
alternative adjuvant strategy but with associated potential complications and 
morbidities these patients would also benefit from improved risk-stratification (11-13).  
 
Histological evidence of vascular invasion (VI) is the only validated histological 
prognostic factor currently used to define risk of relapse in clinical stage I NSGCT (3, 
4), not-with-standing the distinct role that plasma tumor markers play in assessing 
disease state. Tumors with VI have relapse rates of up to 50% and patients may be 
offered adjuvant chemotherapy reducing subsequent relapses to approximately 2% 
(6). In the absence of VI, around 15% patients relapse and surveillance may be a 
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more reasonable option. More accurate stratification of patients for likelihood of 
relapse would improve patient management, decreasing the risk of unneccessary 
treatment with associated side-effects and reducing risks and costs associated with 
over-treatment and excess imaging (14). 
 
A systematic review (4) identified the percentage of Embryonal Carcinoma (%EC) 
within the primary tumor and the proliferation marker MIB1 as promising markers for 
relapse. Both are continuous variables and studies used differing cut-offs with 
variable levels of risk prediction. Univariate odds ratios for relapse range from 2.8 to 
9 (4, 15-18). However %EC and VI were correlated and in multivariate analysis the 
prognostic effect of %EC diminished (4). In a subsequent study, 77% of 
metastasizing tumors showed MIB1 staining in >70% cells, equivalent to an odds 
ratio of 3.18 (95% CI: 1.51, 6.65). However, these data derive from a series of 195 
patients after retroperitoneal lymph node dissections and not strictly a surveillance 
population (19). 
 
Considering novel molecular markers, TGCT resemble primordial germ cells (PGC) 
(20) that physiologically utilize KITLG/KIT and CXCL12/CXCR4 for migration and 
survival during embryological development (21-23) and in the maintenance of the 
spermatogonial stem cell niche (24). Both signalling pathways are implicated in the 
malignant counterpart; KIT is strongly implicated in testicular tumorigenesis with both 
discrete amplification and activating mutations described (20) and TGCT express the 
receptor CXCR4 that can mediate invasive migration towards its ligand, CXCL12 
(25, 26). Importantly, NSGCTs can express CXCL12 in an autocrine fashion and in a 
pilot study containing a high proportion of Embryonal Carcinoma cases (n=80) of 
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TGCT this was associated with reduced risk of relapse (25). Here we investigate this 
feature further for clinical utility alongside VI, %EC and MIB1 staining and in addition 
to other clinicopathological characteristics. 
 
Two recent clinical trials conducted by the Medical Research Council (MRC) 
investigated surveillance strategies in clinical stage I NSGCT and provide a unique 
large cohort of well-characterized stage I NSGCT patients managed on prospective 
protocols. TE08 (NCT00003420) (27) compared two frequencies of CT scanning 
during surveillance of stage I NSGCT. TE22 (NCT00045045) (28) investigated the 
ability of a baseline FDG PET scan to distinguish patients at lower risk of relapse 
who might safely be managed by surveillance. In total 501 patients were managed 
by surveillance, with a relapse rate of 21% (103 patients). 130/501 (26%) had VI, 
although in an unselected population this would be closer to 50%. 
 
To refine treatment stratification in patients diagnosed with stage I NSGCT we set 
out to investigate and validate CXCL12, %EC and MIB1 as biomarkers prognostic for 
relapse. Additional evidence of a prognostic effect for CXCL12 over and above the 
previous pilot data (25) was first sought using a tissue microarray (TMA) comprising 
representative cores from 59 stage I NSGCT patients managed with surveillance. 
We then investigated the markers MIB1, CXCL12 and %EC in the samples from 
stage I NSGCT patients managed by surveillance in the MRC TE08/TE22 clinical 
trials. Finally, we validated a combined prognostic model using VI, CXCL12 and 
%EC in the previous cohort of samples (25). 
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Materials and Methods 
Patients and tumor samples 
This study has national research ethics committee approval (09/MRE00/30) and 
complies with the REMARK guidelines for biomarker studies (29). Samples from 
stage I NSGCT patients managed by surveillance were collected from the Medical 
Research Council (MRC) trials TE08(27, 28). Specifically these were patients 
diagnosed with stage I NSGCT (negative tumour markers and CT scan confirming 
stage I) and enrolled post-operatively into a randomised study of two alternate 
imaging surveillance protocols (TE08) or in the case of TE22, undergoing FDG-PET 
imaging followed by surveillance if negative,  to assess the negative predictive value 
of this scan.Formalin fixed paraffin embedded (FFPE) tumor blocks were available 
for 200/501 (40%) cases; 139 from TE08 and 61 from TE22.10 of the 61 TE22 
patients were not eligible for this study as 7 were PET positive and received adjuvant 
chemotherapy and 1 was PET negative but received adjuvant chemotherapy at the 
patient’s request. 2 cases were lost to follow up. The final trial samples consisted of 
material from 190 patients (Table1). Importantly, this cohort was representative of 
the overall trial sample set with a relapse-free rate of ~78% at 2 years after 
orchidectomy (Supplementary Material Figure S1). Complete tumor cases were 
retrieved from each patient, and a full set of haematoxylin and eosin (H&E) sections 
from tumor for each case were examined by a board certified histopathologist. 
Representative tumour material, to include all significant areas of pathology, was 
selected from each case. VI was assessed as previously described (16). 
Additionally, sections from a TMA containing 0.6mm diameter cores were available 
from Princess Margaret Hospital, Toronto (JS) representing primary tumors from 59 
patients with stage I NSGCT managed by surveillance and a minimum follow-up of 2 
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years (Supplementary Material Table S1).Finally, TMAs comprising material from 80 
patients with stage I non-seminomatous germ cell tumors managed with surveillance 
at the Royal Marsden Hospital (RMH, previously described in (25)) were re-scored 
as per the below by a pathologist (DB) blinded to outcomes. 
 
Sectioning, histology review and staining 
Sections were stained with H&E and assessed to ensure adequate tumor material. 
Sections were deparaffinized prior to staining for CXCL12 (Antibody 79018, 1:100, 
R&D Systems, Minneapolis MN, USA), including positive (tonsillar crypt) and 
negative controls as previously described (25), and MIB1 (Antibody M7240, 1:100, 
Dako). Antibodies were visualized using the Bond Polymer Refine Kit (Leica 
Biosystems, Newcastle, UK). Immunostaining was performed on a Bond max 
automated immunostainer. 
 
Scoring and categorization 
H&E slides were scored for %EC (by DB) as a continuous variable, and then 
additionally grouped as described in previous studies or a new data-derived grouping 
for subsequent analysis.  Immunostaining was scored by two independent 
histopathologists (KT and IC) recording intensity of staining as 0-3 (absent, weak, 
medium and high intensity) and % cells staining positive. Samples where scores 
differed were reviewed and a consensus obtained.  Scores were categorized as 
absent/weak CXCL12 if <1% cells across the whole tumor stained positive for 
CXCL12. A second exploratory analysis was also performed classifying <10% cells 
staining for CXCL12 as CXCL12 absent/weak. Analysis for MIB1 was performed 
separately using both intensity and % cells positive using cut-offs described in the 
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previous studies i.e. ≥70% and ≥40% (15-18) as well as additional exploratory 
analyses. 
 
Statistical methods 
The primary outcome measure was relapse-free rate, measured from the date of 
orchidectomy to the date of relapse confirmation, with relapse-free patients censored 
on the date last known to be alive.  Relapse free rates on Kaplan Meier survival 
curves were compared by the logrank test, with an initial assessment of the 
independence of %EC, CXCL12 and MIB1 over VI determined by logrank tests 
stratified for VI.  Subsequently, a proportional hazards regression model was fitted to 
adjust for baseline clinical variables, VI, %EC, MIB1 and CXCL12 staining, using 
forward and backwards stepwise selection. Chi squared tests were used to 
investigate the association of %EC and CXCL12/MIB1 staining with clinico-
pathological variables.  
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Results 
TMA CXCL12 expression and outcome 
To investigate CXCL12 as a marker for relapse prior to application to the clinical trial 
sample sets, we first studied the TMA representing 59 cases.  25/59 cases (42.4%) 
demonstrated moderate/strong expression of CXCL12 cells of which 3 had relapsed 
(RFR 88.0%). Of the 34 patients with absent/weak staining for CXCL12, 11 had 
relapsed (RFR 67.6%, log rank test p=0.68). Although not reaching statistical 
significance, the rates of CXCL12 expression and subsequent relapse were 
consistent with previous data [25] and analysis of CXCL12 expression was taken 
forward to TE08/TE22 samples. 
 
TE08/22 – CXCL12 and relapse 
Samples representing 182/190 samples from patients in the TE08 and TE22 trials 
were assessable for CXCL12 staining (Table 1; Figure 1A,B,C,D). Using <1% as the 
cut off, 37 (20.3%) tumors were classified as absent/weakwith the other 145 (79.7%) 
moderate/strong(as scored by two pathologists, κ=0.465, p<0.001). In an exploratory 
analysis, a <10% cut off was also assessed and produced a similar 
performance(Supplementary Table S2 and Figure S2). Therefore either cut-off may 
be used.There was no association between CXCL12 and VI, the presence of 
seminomatous elements or raised markers pre-orchidectomy.  There was however a 
strong association with the presence of Embryonal Carcinoma which was more 
prevalent in those with absent/weak staining, (75.7% vs 30.3% of those with 
moderate/high staining, chi-square p < 0.001). The logrank test shows evidence of a 
prognostic impact, alone and stratified by VI (p=0.006, Table 2) for CXCL12 with 
reduced relapse-free rate in the absent/weak group (Figure 2A).  In VI+ve patients, 
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CXCL12 further stratified relapse rates; 56 patients with VI but moderate/strong 
staining had a 2-year RFR of 62.4% versus 11 patients with VI and absent/weak 
staining for CXCL12 where a RFR of 27.3% was observed (95% CI 1-53.6%). 
 
TE08/22 - %EC and relapse  
177/190 patients were assessable for %EC (Table 1; Figure 1E,F,G). This showed a 
bimodal distribution, with clusters at 0% and 100% and a relatively even spread of 
the remaining values between these levels. %EC was significantly higher in patients 
with VI (median 70% vs 20%, Mann Whitney test p=0.013), and also in those with 
absent/weak CXCL12 intensity (medians 100% vs 20% for moderate/strong, 
p<0.001) and with presence of MIB1 staining (medians 50% vs 10%, p=0.012). 
 
%EC was assessed as in previous reports as a continuous variable, a binary 
variable (presence/absence) and applying previously reported cut-offs, (<45% 46-
70%, >70%; above or below 50%) (4). In addition, to better reflect the unusual 
distribution of %EC, a data-derived categorization was investigated, formed by 
dividing the data initially into approximate quintiles (0%, 1-25%, 26-75%, 76-99%, 
100%), collapsing groups with similar relapse free rates to create an “optimal” 
categorisation (≤25%, 26-99%, 100%). With the exception of presence/absence of 
EC, higher %EC was associated with higher relapse rates (Figure 2B, Table 2), 
independent of VI, for all categorizations.   
 
TE08/TE22 - MIB1 and relapse 
179 cases were assessable for MIB1 staining; 45 (25.1%) were MIB1 weak on both 
intensity and proportion of cells staining (Table 1; Figure 1H). There was a significant 
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association of both MIB1 intensity and proportion of cells staining for MIB1 with 
decreasing likelihood of the tumor containing seminomatous elements (Mann 
Whitney test p<0.001) and increasing likelihood of VI (Mann-Whitney test p=0.004 
for intensity and p<0.001 for % cells staining). 
 
There was no evidence of prognostic value for MIB1 staining intensity (logrank test 
for trend p=0.26) nor for the proportion of cells staining positive for MIB1, either when 
analysed as per previous reports (≥70% and ≥40%), as quartiles or using a log rank 
test for trend. In contrast to previous studies, only 5/179 patients (3%) had MIB1 
staining in >70% of cells. The main distinction observed was between the 45 
samples with weak vs any staining for MIB1 (Table 2). Analyzing the samples in this 
binary fashion (MIB1 positive or negative) has a prognostic effect (univariate 
analysis), which was reduced after stratification for VI (Table 2). 
 
TE08/TE22 multivariate analyses 
Multivariate analyses were performed on the 177 patients with complete data to 
assess the additional prognostic value of these factors over and above the 
presence/absence of VI and clinical variables, specifically VI (yes/no), histology type, 
seminomatous elements present/absent, age (continuous variable), alpha feto 
protein (AFP) raised pre-orchidectomy (yes/no), human chorionic gonadotrophin 
(HCG) raised pre-orchidectomy (yes/no), CXCL12 expression, MIB1 staining 
(high/weak), %EC (as a continuous variable), EC present/absent, and %EC 
categorised according to previous studies, (<45, 46-79, >80%; <50% vs ≥50% (4)) 
and %EC categorised according to the optimal cut offs for this dataset (<25%, 26-
99% and 100%). 
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Both forward and backwards stepwise model selection procedures were used which 
all led to a model (Supplementary Table S3) including only VI and %EC (continuous 
variable). Dropping EC as a continuous variable but keeping all the other variations, 
the model includes only VI and %EC, using the “optimal” categorization (Figure 2B). 
However, if %EC is used as previously reported (4), then VIand CXCL12, but not 
%EC, are retained as independent variables (Figure 2A). 
Components of both groupings have potential clinical utility in defining subsequent 
relapse risk, and as such we also present a combined model (Figure 3A) using 3 
prognostic groups. Specfically these are a) VI negative, <100% EC and any 
CXCL12, b) VI negative,100% EC any CXCL12 or VI positive, any EC and mod/high 
CXCL12 and c) VI +ve, any EC, absent/weak CXCL12 with 2 year RFRs of 94.3% 
(95% CI 89.4%, 99.2%), 63.9% (52.9%, 74.9%) and 30% (1.6%, 58.4%) respectively 
(Logrank X2=38.6 on 2.df, p<0.001). 
 
Validation of model combining VI, CXCL12 and %EC on RMHcohort. 
Staining characterisics of the cohort of 80 RMH patients managed with surveillance 
mirror those of the TE08/TE22 patients and are detailed in Table 3. Overall this 
cohort experienced a 2 year relapse-free rate (RFR) of 60% (95% CI 59%-71%). For 
patients with VI this was 47% (31-63%) as opposed to 69% without (54-83%). 
CXCL12 expression was prognostic as previously described with tumors 
absent/weak for CXCL12 having a 2 year RFR a relapse rate of 34% (18-50%)  
whereas tumors with moderate/high statining for CXCL12 having an RFR of 80% 
(68-92%), HR 0.24 (95% CI 0.11-0.49) p<0.001. CXCL12 expression retained 
additional prognostic value over and above VI (stratifed log rank p<0.001).Finally 
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%EC was also prognostic in this cohort, with the 2year RFR ranging from 79%(61-
87) for patients with <=25%EC, through 64% (47-82%) with 26-99% EC and 48% 
(31-66%) in cases that were 100%EC( p=0.04).  Using the combined model 
developed above, the three risk groupings have 2 RFR of 81.5%(66.8-96.2) for 
patients that were VI negative and %EC<100, 64.5%(47.6-81.4) for those that were 
VI negative and 100%EC or VI positive and moderate/high expression of CXCL12 
and a 2 year RFR of just 27.3%(8.7-45.9) for those that had evidence of VI but 
absent/weak expression of CXCL12 (Figure 3B, log rank Mantel-Cox <0.001). 
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4. Discussion 
Using samples from stage I NSGCT patients managed by surveillance on 
prospective clinical trials, we have demonstrated that CXCL12 expression and %EC 
in the primary tumor are both predictors of relapse independently of VI.  Importantly, 
samples obtained for this study were representative of the total trial populations 
(~78% relapse free rate at 2 years, by which point most relapses have usually 
occurred) and hence represent patients with stage I NSGCT in general. This 
provides prognostic information of potential clinical relevance over and above the 
presence/absence of histological evidence of VI being able to identify patients at low, 
moderate or very high risk of relapse (Tables 2, S2 and 3).  However, %EC and 
CXCL12 are strongly inversely correlated and in multivariate analyses one or the 
other – but not both - are selected in addition to VI, depending on how %EC is 
analyzed.  This gives two alternative prognostic models, as illustrated in figure 2A 
and B. While the multivariate analysis does not support a model containing VI with 
both %EC and CXCL12,  there are unique characteristics of each combination that 
an ideal model would combine, specifically identification of a very high risk group 
(VI+, CXCL12 absent) and identification of VI-ve patients who have a prognosis 
closer to that of VI+ve (VI-ve, 100% EC).  We therefore derived an exploratory model 
that combines these elements into 3 prognostic groups (Figure 3A).Using a cohort of 
cases previously characterised for CXCL12 (25), through the additional inclusion of 
%EC scores and VI we demonstrate the validity of this model (Figure 3B). 
 
As shown previously (4), %EC is a subjective analysis. CXCL12 expression (<1% or 
<10% of cells staining positive as thresholds to classify as CXCL12 absent) together 
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with VI is a potentially more reproducible approach to determining prognosis, and 
one that identifies a small group of patients with distinctly poorer prognosis.  
 
Adjuvant chemotherapy is highly effective treatment and even 1 cycle, currently 
being tested in a UK phase II single arm study (BEP 111), can reduce the risk of 
recurrence to <4% (11, 13, 30, 31). This use of adjuvant BEP has been criticized for 
exposing a high proportion of patients who would not go on to relapse to intensive 
chemotherapy. Refining the current risk model (utlizing lymphovascular invasion 
alone) would therefore be of clinical utility, allowing adjuvant therapy to be focused 
on those at highest risk. Our analysis in this cohort supports our previous study in 
showing that CXCL12 immunohistochemistry can add valuable additional prognostic 
information to the model based on VI, particularly in identifying a small cohort of 
patients with a very high risk of relapse. It also in identifies groups for whom 
surveillance, potentially using reduced intensity follow-up (at least to the reduced 
frequency arm used in TE08 (27)) may be most appropriate, and those  suitable for 
either surveillance or adjuvant therapy depending on personal preferences. 
Identifying high-risk patients for minimal effective adjuvant therapy will ultimately 
reduce long-term side-effects for the stage I NSGCT population as a whole. 
 
The prognostic value of MIB1 was analysed in a number of ways looking at intensity 
and percentage of cells both separately and combined and including previously used 
categorizations (15-18, 32).. Although patients with weak staining have a better 
prognosis than those with high MIB1 staining, MIB1 staining was associated with VI 
and in multivariate analysis does not add clear independent prognostic value. 
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The prognostic value of CXCL12 expression demonstrated here is consistent with a 
growing body of evidence for the CXCL12/CXCR4 axis supporting the male germ 
cell niche and the metastatic spread of cancers, including this possibility in germ cell 
tumors (20, 22, 24, 25, 26, 33). CXCR4 expression is associated with invasion and 
metastases in a range of tumor types where lower levels of CXCL12 in tumors 
predict a reduced risk of metastatic dissemination (34, 35). Furthermore in breast 
cancer, lower levels of plasma CXCL12 appear to be associated with increased risk 
of metastatic relapse (36). That autocrine expression of CXCL12 consistently 
reduces the subsequent risk of relapse in stage I NSGCT (independent from 
histological VI) suggests the abrogation of a chemokine gradient (towards CXCR4) 
might prevent extravasation into the vascular compartment and/or invasion at 
metastatic sites. To this end, assessment of stromal and/or plasma CXCL12 might 
provide additional prognostic information. The apparent association with histological 
subtypes of TGCT requires further work, aligned with a better understanding of how 
these tumours develop from the in situ counterpart. Further investigations will inform 
on these and other potential mechanisms of dissemination and relapse (37) in 
NSGCT patients.   
 
As a paradigm of protecting future quality of life in an essentially curable diseasea 
prospective study is recommended (potentially also investigating novel imaging 
strategies in an effort to minimize radiation exposure e.g. MRI)  to further validate the 
prognostic value of CXCL12 and/or %EC expression in addition to the 
presence/absence of histological VI.  This is anticipated to lead to the ability to 
identify patients diagnosed with stage I NSGCT at high risk of relapse to be 
considered for adjuvant therapy whilst others are safely surveilled. 
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Table 1. Histological subtype, % Embryonal Carcinoma, tumour marker status and 
immunohistochemistry for CXCL12 and MIB1 for 190 stage I NSGCT primary 
tumours from patients treated in the TE08/TE22 clinical trials. EC - embryonal 
carcinoma; CC - choriocarcinoma; AFP - alpha fetoprotein; HCG - human chorionic 
gonadotrophin. 
 Vascular invasion  Total 
No Yes  
N % N % N % 
 Histology 
Pure EC 23 19% 18 27% 41 22%
Mixed NSGCT 79 65% 39 57% 118 62%
Yolk sac 8 7% 3 4% 11 6%
Differentiated 
Teratoma 
9 7% 1 2% 10 5%
Other type 3 3% 7 10% 10 5%
    
EC presence 
EC absent 29 26% 9 14% 38 22%
EC present 83 74% 56 86% 139 79%
Not known 10 3  13 
% EC Optimal 
categories 
<=25% 60 54% 20 31% 80 45%
26-99% 29 26% 27 42% 56 32%
100% 23 21% 18 28% 41 23%
Not known 10 3  13 
AFP pre-orchidectomy normal  53 43% 25 37% 78 41%raised  69 57% 43 63% 112 59%
HCG pre-orchidectomy normal  65 53% 29 43% 94 50%raised  57 47% 39 57% 96 50%
CXCL12 (≤1%=    
 weak/absent) 
Insufficient  tumor 7 6% 1 2% 8 4%
absent/weak 26 21% 11 16% 37 20%
moderate/strong 89 73% 56 82% 145 76%
MIB1 staining 
Weak 37 33% 8 12% 45 25%
High 77 68% 57 88% 134 75%
Not assessable 8 3  11 
Total 122 64% 68 36% 190 100%
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Table 2.  Univariate and stratified logrank test results for factors of interest in 177 
cases with complete data. 
  
No. Pts 2 yr RFR 95% CI 
Log rank 
p-value 
Stratified (by 
VI) log rank p-
value 
Vascular invasion           
absent 112 88.3 (82.2, 94.4) <0.001 n/a 
present 65 58.3 (46.0, 70.6)     
CXCL12           
mod/high,  no VI 87 90.7 (84.6, 96.8)     
mod/high,  VI 55 63.7 (50.6, 76.8)     
Sub-total mod/high 142 80.4 (73.7, 87.1) 0.078 0.009 
absent /weak, no VI 25 80.0 (64.3, 95.7)     
absent /weak,  VI 10 30.0 (1.6, 58.4)     
Sub-total absent 35 65.7 (50.0, 81.4)     
MIB1           
Weak, no VI 35 91.4 (82.2, 99.9)     
Weak, VI 7 100.0 (39.8, 99.9)     
Sub-total weak 42 92.8 (85.0, 99.9) 0.007 0.045 
High, no VI 76 86.7 (79.1, 94.3)     
High, VI 56 53.7 (40.4, 67.0)     
Sub-total high 132 73.0 (65.4, 80.6)     
EC (Present/absent)           
Absent, no VI 29 96.3 (89.2, 99.9)     
Absent, VI 9 66.7 (35.9, 97.5)     
Sub-total absent 38 89.2 (79.2, 99.2) 0.096 0.243 
Present, no VI 83 85.4 (77.8, 93.0)     
Present, VI 56 56.8 (43.5, 70.1)     
Sub-total present 139 74.3 (66.9, 81.7)     
EC (optimal categories)           
≤25%EC, no VI 60 94.9 (89.2, 99.9)     
≤25%EC, VI 20 68.1 (46.9, 89.3)     
Sub-total ≤25% 80 88.4 (81.3, 95.5)     
26-99%EC, no VI 29 93.1 (83.9, 99.9)     
26-99%EC, VI 27 57.3 (38.1, 76.5) <0.001 0.006 
Sub-total 26-99% 56 76.4 (65.2, 87.6)     
100% EC, no VI 23 63.6 (43.4, 83.8)     
100%EC, VI 18 50.0 (26.9, 73.1)     
Sub-total 100% 41 57.5 (42.2, 72.8)     
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Table 3.  Tumor characteristics (VI, CXCL12 and %EC) for 80 stage I NSGCT RMH 
patients managed by surveillance 
 
No Vascular 
Invasion 
Vascular invasion  
+ Total 
N % N % N % 
EC% <=25% 14 33.3% 5 13.9% 19 24.4% 
26-99% 13 31.0% 15 41.7% 28 35.9% 
100% 15 35.7% 16 44.4% 31 39.7% 
CXCL12 
Intensity 
0 11 26.2% 19 50.0% 30 37.5% 
1 2 4.8% 3 7.9% 5 6.3% 
2 9 21.4% 5 13.2% 14 17.5% 
3 20 47.6% 11 28.9% 31 38.8% 
CXCL12 Absent/low 13 31.0% 22 57.9% 35 43.8% 
Moderate/high 29 69.0% 16 42.1% 45 56.3% 
Proposed 
grouping 
No VI, %EC <100 27 64.3% 0 0.0% 27 33.8% 
No VI and 100% EC 
or 
VI and mod/high 
CXCL12 
15 35.7% 16 42.1% 31 38.8% 
VI and absent/low 
CXCL12 0 0.0% 22 57.9% 22 27.5% 
TOTALS  42 100% 38 100% 80 100% 
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Figure Legends: 
Figure 1. Representative staining of stage I non-seminomatous germ cell 
tumor samples. Immunohistochemistry for CXCL12 staining A negative B <10% C 
~30% and D 100% positive. E  Haematoxylin and Eosin staining showing a 
combined seminomatous (bottom of photomicrograph) and non-seminomatous 
tumour (top) composed of less than 10% embryonal carcinoma. F Tumor composed 
of 25% embryonal carcinoma and 75% yolk sac tumor. The yolk sac and embryonal 
carcinoma are intermingled in a polyembryomatous fashion, mimicking the earliest 
stages of embryonic development. G Tumor entirely composed of embryonal 
carcinoma. H  Embryonal carcinoma showing 75% positivity for MIB1 
immunohistochemistry. (Scale bar, 100 microns). 
Figure 2. Relapse-free survival data for:A182 patients with stage I NSGCT 
managed by surveillance with the MRC TE08 and TE22 clinical trials, stratified by 
vascular invasion (VI) and immunohistochemistry for CXCL12 in combination with 
the presence/absence of histological VI (stratified log rank test p=0.006).B 177 
patients with stage I NSGCT managed with surveillance stratified by %EC and VI, 
illustrated using optimal cut-offs for %EC. 
Figure 3. Relapse free survival data for:A177 patients with stage I NSGCT 
managed with surveillance according to data-derived risk groups.B An independent 
cohort of 80 patients with stage I NSGCT managed with surveillance stratified by the 
risk grouping derived in A. 
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Figure 2 
A 
B 
Logrank X2=34.8 on 3.df, p<0.001 
Logrank X2=34.8 on 3.df, p<0.001 
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Figure 3 
A 
B 
Logrank X2=38.6 on 2.df, p<0.001 
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